Zuoshouyisheng (ZSYS), an AI healthcare system developer, has bagged RMB 100 million (USD 15.5 million) in Series B financing led by Qiming Venture Capital along with the participation of Haier Capital and other investment firms. The funds will be put toward R&D for new AI products and commercial applications.
The company’s core product is an “AI doctor” platform. ZSYS utilizes deep learning and big data technologies to interpret the symptoms of patients and generate diagnoses. The company says the platform can empower medical practitioners and help them reach more patients, and in turn give the public access to better healthcare and medical services.
ZSYS’s AI doctor platform spans 35 medical specialties and can diagnose more than 6,000 diseases, according to the company’s website. ZSYS mainly collaborates with customers through a SaaS business model, providing its AI-empowered healthcare system to hospitals, pharmaceutical companies, employers, and insurers.
Pharmaceutical companies that utilize ZSYS’s system can glean real-time data from patients. Insurance companies can use the platform to monitor the physical conditions of policyholders.
“Zuoshouyisheng applies AI technology to the medical field, and its intelligent solutions cover various scenarios. This can significantly improve treatment outcomes and the experiences of patients,” said Jinda Gao, a principal of Qiming Venture Partners.
Besides its AI doctor platform, ZSYS has developed a device that can automatically generate medical records based on conversations between doctors and patients.
ZSYS is currently exploring the potential for new B2C products.
The number of internet hospitals—facilities where patients use web-based tools to connect with medical practitioners from top-notch medical centers in major cities—has gone from around 100 in 2018 to more than 1,600 in June 2021, according to Xinhua. The pandemic, as well as public policies, has motivated hospitals to develop intelligent medical care and provide services online.
Read this: Ant Group-backed MediTrust Health gets USD 300 million in Series C, plans IPO by end of 2021
36Kr Connection features translated and adapted content published by 36Kr. This article was originally written by Cai Shuning for 36Kr. It was translated and adapted by Jiaxing Li.
